Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea

Journal of Medical Virology

Volumn 85, Issue 4, 2013, Pages 575-582

  Min, Jung Ah ^a   Yoon, Yeongsil ^b   Lee, Hyeok Jin ^b   Choi, Jihye ^c   Kwon, Min ^c   Kim, Kisang ^b   Lee, Chang Uk ^a   Kim, Dai Jin ^a,b   Yun, Haesun ^b  

^a The Catholic University of Korea   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

HBV; HCV; HIV; Injecting drug use; Prevalence, intravenous substance abuse

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; ARTICLE; DRUG USE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTING DRUG USER; MALE; MIXED INFECTION; PREVALENCE; SEROPREVALENCE; SOUTH KOREA;

ADULT; AGED; COINFECTION; COMORBIDITY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84873953999     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23523     Document Type: Article

References (58)

1. Aceijas C, Rhodes T. 2007. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 18:352-358.
2. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Marracino M, Gambardella M, Giordano M, Ruggiero G. 2001. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 46:1677-1683.
3. Argentini C, Genovese D, Dettori S, Rapicetta M. 2009. HCV genetic variability: From quasispecies evolution to genotype classification. Future Microbiol 4:359-373.
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
5. Beld M, Penning M, McMorrow M, Gorgels J, van den Hoek A, Goudsmit J. 1998. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol 36:872-877.
6. Bowden S, McCaw R, White PA, Crofts N, Aitken CK. 2005. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. J Viral Hepat 12:322-324.
7. Cavlek TV, Maric J, Katicic L, Kolaric B. 2011. Hepatitis C virus antibody status, sociodemographic characteristics, and risk behaviour among injecting drug users in Croatia. Cent Eur J Public Health 19:26-29.
8. Centers for Disease Control and Prevention. 2003. Transmission of hepatitis B and C viruses in outpatient settings-New York, Oklahoma, and Nebraska, 2000-2002. MMWR Morb Mortal Wkly Rep 52:901-906.
9. Chu C, Lee S. 2008. Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 23:512-520.
10. Ciccozzi M, Zehender G, Cento V, Lo Presti A, Teoharov P, Pavlov I, Bogdanova V, Perno CF, Ciotti M. 2011. Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users. J Med Virol 83:1565-1570.
11. Cook PA, McVeigh J, Syed Q, Mutton K, Bellis MA. 2001. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 96:1787-1797.
12. Degenhardt L, Hall W. 2012. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379:55-70.
13. Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG. 2010. Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 82:263-270.
14. Elefsiniotis IS, Hero B, Mariolis A, Pantazis KD, Fotos NV, Ketikoglou I, Saroglou G. 2005. Serological profile of HBV infection and liver histopathology among injecting drug users with chronic HCV infection in Greece. Eur J Intern Med 16:496-500.
15. Esteban JI, Sauleda S, Quer J. 2008. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148-162.
16. Fagerström KO. 1978. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235-241.
17. Gyarmathy VA, Neaigus A, Ujhelyi E. 2009. Vulnerability to drug-related infections and co-infections among injecting drug users in Budapest, Hungary. Eur J Public Health 19:260-265.
18. Hagan H, Thiede H, Des Jarlais DC. 2004. Hepatitis C virus infection among injection drug users: Survival analysis of time to seroconversion. Epidemiology 15:543-549.
19. Hope V, Parry JV, Marongui A, Ncube F. 2012. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference? J Viral Hepat 19:55-64.
20. Kalinina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, Mukomolov S, Magnius LO. 2001. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol 65:517-524.
21. Kee MK, Lee JH, Chu C, Lee EJ, Kim SS. 2009. Characteristics of HIV seroprevalence of visitors to public health centers under the national HIV surveillance system in Korea: Cross sectional study. BMC Public Health 9:123.
22. Kim HS, Choo DH. 1996. Prevalence of hepatitis C, B, and human immunodeficiency virus among drug users and chronic alcoholic patients in Korea. Korean J Intern Med 11:38-43.
23. Kim JM, Cho GJ, Hong SK, Chang KH, Chung JS, Choi YH, Song YG, Huh A, Yeom JS, Lee KS, Choi JY. 2003. Epidemiology and clinical features of HIV infection/AIDS in Korea. Yonsei Med J 44:363-370.
24. Lee JH, Hong KJ, Wang JS, Kim SS, Kee MK. 2010. Estimation of hospital-based HIV seroprevalence as a nationwide scale by novel method; 2002-2008 in Korea. BMC Public Health 10:739.
25. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP. 2008. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 372:1733-1745.
26. McGovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, Kim AY. 2009. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 200:877-881.
27. Mehta SH, Vogt SL, Srikrishnan AK, Vasudevan CK, Murugavel KG, Saravanan S, Anand S, Kumar MS, Ray SC, Celentano DD, Solomon S, Solomon SS. 2010. Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India. Indian J Med Res 132:706-714.
28. Micalessi MI, Gerard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. 2008. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. J Med Virol 80:640-645.
29. Miller CL, Johnston C, Spittal PM, Li K, Laliberte N, Montaner JS, Schechter MT. 2002. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 36:737-742.
30. Mizokami M, Nakano T, Orito E, Tanaka Y, Sakugawa H, Mukaide M, Robertson BH. 1999. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 450:66-71.
31. Muasya T, Lore W, Yano K, Yatsuhashi H, Owiti FR, Fukuda M, Tamada MY, Kulundu J, Tukei J, Okoth FA. 2008. Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya. East Afr Med J 85:318-325.
32. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. 2011. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378:571-583.
33. Novais AC, Lopes CL, Reis NR, Silva AM, Martins RM, Souto FJ. 2009. Prevalence of hepatitis C virus infection and associated factors among male illicit drug users in Cuiaba, Mato Grosso, Brazil. Mem Inst Oswaldo Cruz 104:892-896.
34. Potthoff A, Manns MP, Wedemeyer H. 2010. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 11:919-928.
35. Pungpapong S, Kim WR, Poterucha JJ. 2007. Natural history of hepatitis B virus infection: An update for clinicians. Mayo Clin Proc 82:967-975.
36. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. 2010. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis 14:e28-e33.
37. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F. 2008. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652-657.
38. Raimondo G, Caccamo G, Filomia R, Pollicino T. 2012. Occult HBV infection. Semin Immunopathol (in press). DOI: 10.1007/s00281-012-0327-7
39. Rantala M, van de Laar MJ. 2008. Surveillance and epidemiology of hepatitis B and C in Europe-A review. Euro Surveill 13: pii=18880.
40. Removille N, Origer A, Couffignal S, Vaillant M, Schmit JC, Lair ML. 2011. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations. BMC Public Health 11:351.
41. Roman F, Hawotte K, Struck D, Ternes AM, Servais JY, Arendt V, Hoffman P, Hemmer R, Staub T, Seguin-Devaux C, Schmit JC. 2008. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol 14:1237-1243.
42. Rosen HR. 2011. Clinical practice. Chronic hepatitis C infection. New Engl J Med 364:2429-2438.
43. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. 1993. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 88:791-804.
44. Scott JD, Gretch DR. 2007. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA 297:724-732.
45. Sereno S, Perinelli P, Laghi V. 2009. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 45:354-357.
46. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567.
47. Simmonds P, Bukh J, Combet C, Delage G, Enomoto N, Feinstone S, Halfon P, Inchausp G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky J, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel H, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
48. Spielberger CD, Gorsuch RL, Lushene RE. 1970. Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press.
49. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, Hankins CA. 2010. HIV and risk environment for injecting drug users: The past, present, and future. Lancet 376:268-284.
50. Suh DJ, Jeong S. 2006. Current status of hepatitis C virus infection in Korea. Intervirology 49:70-75.
51. Te HS, Jensen DM. 2010. Epidemiology of hepatitis B and C viruses: A global overview. Clinics Liver Dis 14:1-21, vii.
52. Torbenson M, Thomas DL. 2002. Occult hepatitis B. Lancet Infect Dis 2:479-486.
53. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. 2004. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:51-57.
54. Tran SD, Williams AB, Truong HT, Do NH. 1998. Risk factors for HIV seropositivity in a sample of drug users in drug treatment in Ho Chi Minh City, Vietnam. J Acquir Immune Defic Syndr Hum Retrovirol 17:283-287.
55. Turner K, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May M, Taylor A, De Angelis D, Cameron S, Parry J, Lyons M, Goldberg D, Allen E, Hickman M. 2011. The impact of needle and syringe provision and opiate substitution therapy on the incidence of Hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 106:1978-1988.
56. Wylie JL, Shah L, Jolly AM. 2006. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 6:229.
57. Yoon S, Pae C, Lee H, Choi B, Kim T, Lyoo IK, Kwon D, Kim D. 2005. Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population. Neurosci Res 53:391-395.
58. Yun H, Kim D, Kim S, Kang S, Jeong S, Cheon Y, Joe K, Gwon DH, Cho SN, Jee Y. 2008. High prevalence of HBV and HCV infection among intravenous drug users in Korea. J Med Virol 80:1570-1575.